American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab
ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
- The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
- Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
- Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
- The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.